BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25132027)

  • 1. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
    Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
    Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
    Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
    Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
    Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
    Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].
    Tokura H; Fujisaki M; Takahashi T; Takigawa Y; Onouchi S; Matsuda K; Hirata A
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1071-3. PubMed ID: 22790041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
    Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
    Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical benefit of high-dose toremifene for metastatic breast cancer.
    Koike K; Edo M; Higaki M; Kitahara K; Satou S; Noshiro H
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
    Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
    Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
    Sakurai K; Enomoto K; Amano S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Yamamoto Y; Ishikawa T; Hozumi Y; Ikeda M; Iwata H; Yamashita H; Toyama T; Chishima T; Saji S; Yamamoto-Ibusuki M; Iwase H
    BMC Cancer; 2013 May; 13():239. PubMed ID: 23679192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
    Kurozumi S; Takeo T; Ikeda F; Horiguchi J; Takeyoshi I; Ito H
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):93-6. PubMed ID: 21368465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
    Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
    Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
    Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
    Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.